CNP-103

PreclinicalSmall molecule

CCOUR Pharmaceutical Development Company, Inc.

CNP-103 is one of 52 small molecule programs targeting Type 1 Diabetes Mellitus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 Diabetes MellitusRecruiting

Type 1 Diabetes MellitusPreclinical

Recruiting

Competition

Competitive Landscape

67 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

2 2

Mounjaro

Eli Lilly

Approved

1 3

Farxiga

Olumiant

Ozempic

Brethine

Estrace

Rocaltrol

Neoral

Opzelura

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Type 1 Diabetes Mellitus

NCT06783309

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 With Recent Onset Stage 3 Type 1 Diabetes

Recruiting·CCOUR Pharmaceutical Development Company, Inc.·Preclinical·NCT06783309·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CNP-103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CNP-103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CNP-103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — COUR Pharmaceutical Development Company, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCOUR Pharmaceutical Development Company, Inc.

CNP-103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News